VYNE Therapeutics (NASDAQ:VYNE) Announces Earnings Results

Posted by Stanley Muller on Aug 13th, 2026

VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) released its earnings results on Thursday. The company reported ($3.51) EPS for the quarter, missing the consensus estimate of ($0.18) by ($3.33), FiscalAI reports. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. The firm had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.20 million.

VYNE Therapeutics Stock Performance

Shares of VYNE Therapeutics stock traded down $0.23 during midday trading on Thursday, hitting $28.32. 93,278 shares of the company traded hands, compared to its average volume of 44,151. The stock has a market cap of $18.98 million, a price-to-earnings ratio of -74.54 and a beta of 2.00. The firm’s fifty day moving average price is $32.72 and its 200-day moving average price is $31.48. VYNE Therapeutics has a 12 month low of $14.03 and a 12 month high of $79.75.

VYNE Therapeutics Announces Dividend

The business also recently declared a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were paid a $19.00 dividend.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of VYNE Therapeutics in a research note on Monday, May 4th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Get Our Latest Report on VYNE

Institutional Trading of VYNE Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. KVP Capital Advisors LP bought a new stake in shares of VYNE Therapeutics during the fourth quarter worth $290,000. XTX Topco Ltd bought a new position in shares of VYNE Therapeutics in the 4th quarter valued at $46,000. ADAR1 Capital Management LLC bought a new position in shares of VYNE Therapeutics in the 4th quarter valued at $147,000. Anson Funds Management LP acquired a new stake in shares of VYNE Therapeutics during the 4th quarter valued at $739,000. Finally, Nantahala Capital Management LLC acquired a new stake in shares of VYNE Therapeutics during the 4th quarter valued at $580,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

About VYNE Therapeutics

(Get Free Report)

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.